MEDIAN Technologies

140 articles with MEDIAN Technologies

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• Median Technologies Appoints Jean-Christophe Montigny as Chief Financial Officer and Member of the Executive Committee

  7/29/2021

  Median Technologies (Paris:ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer.

• Median Technologies: Financial Communication Schedule for the Second Half Of 2021

  7/9/2021

  Median Technologies, announces the publication date for its 2021 half year results and its Q3, 2021 business performance :

• Median Technologies' Business Continues to Grow at a Steady Pace in the First Half of 2021 (Unaudited Figures)

  7/8/2021

  For the first half of 2021, Median Technologies' revenue amounts to €10.1m, up 71% compared to the H1 2020 revenue, which stood at €5.9m.

• Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth

  4/8/2021

  2020, a record year with revenue of €13.5m, up 51% on 2019 2020 results in line with expectations Acceleration of the growth dynamic in the first quarter of 2021 with revenue of €5.2m, an increase of 86% compared to Q1, 2020.

• iBiopsy®: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)

  2/16/2021

  Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.

• iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)

  2/9/2021

  The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy®’s AI technology, applied to liver fibrosis characterization

• Median Technologies Records a 51 % Increase of Its 2020 Annual Revenue (Unaudited Figures)

  1/14/2021

  2020 full year revenue of €13.5 million, increased by 51 % compared to 2019 (€9 million) As of December 31, 2020, order backlog of €51.7 million, up 35 % compared to December 31, 2019 Cash and cash equivalents of €16.3 million as of December 31, 2020

• Median Technologies: Financial Communications Schedule for the First Half of 2021

  1/5/2021

  Median Technologies, The Imaging Phenomics Company® announces the publication date for its 2020 results

• Median Technologies Records Its Eighth Consecutive Quarter of Revenue Growth

  10/20/2020

  Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m) Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019 Order backlog of €50.7m Cash and cash equivalents of €17.3m

• Median Technologies Announces its H1 2020 Results

  10/14/2020

  Revenue surges 47.9% compared with the first half of 2019 at €5.9m Order backlog up 40% over six months to €53.6m Cash and cash equivalents of €19.4m SOPHIA ANTIPOLIS, France--( BUSINESS WIRE )-- Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, today announced its results for the first half of 2020. On October 12, 2020, the Board of Directors of Median Technologies approved the consolidated fi

• Median Technologies: Financial Communications Schedule for the Second Half Of 2020

  8/27/2020

  Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2020: Publication Date 2020 half year results October 14, 2020* *Release after the close of trading About Median Technologies: Median Technologies provides innovative imaging solutions and servic

• Half Year Median Technologies Liquidity Contract Statement Contracted with Louis Capital Markets UK LLP

  7/10/2020

  Regulatory News: Under the liquidity contract entrusted by Median Technologies (Paris:ALMDT) (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the liquidity account as of June 30, 2020: 32,518 shares €77,124.37 in cash Transactions during the first half 2020: BUY 114,265 shares 455,351.48 EUR

• Median Technologies Is Awarded the Euronext European Rising Tech Label

  7/6/2020

  Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mi

• Median Technologies to Host a Live Webcast and Provide a Company Update on July 9th, 2020

  7/1/2020

  Median Technologies (Paris:ALMDT), the Imaging Phenomics Company® announced today that Fredrik Brag, CEO of Median Technologies, will provide a company update on July 9th, 2020 at 11:00 am CEST during a webcast.

• Median Technologies Appoints Oern Stuge MD, MBA, to Its Board of Directors

  6/25/2020

  Median Technologies, the Imaging Phenomics Company® announced that Oern Stuge MD, MBA, has joined its Board of Directors, chaired by Oran Muduroglu.

• 

  BioSpace Global Roundup, June 18

  6/18/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.

• Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer

  6/17/2020

  Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers

• Median Technologies: Liquidity Contract Transfer to Louis Capital Markets

  5/4/2020

  Median Technologies is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi charter.

• Median Technologies Records Its Best Quarterly Performance and Joins Forces With Biopharmaceutical Companies in the Fight Against Covid-19

  4/28/2020

  Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company®, provides an update on its performance for Q1 2020 and a review of its commitment to tackle Covid-19.